David B Savage

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi request reprint A clinical approach to severe insulin resistance
    David B Savage
    Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK
    Endocr Dev 11:122-32. 2007
  2. doi request reprint Lipodystrophy: metabolic insights from a rare disorder
    Isabel Huang-Doran
    Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke s Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, UK
    J Endocrinol 207:245-55. 2010
  3. ncbi request reprint Metabolic insights from extreme human insulin resistance phenotypes
    Anna Stears
    Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge, UK
    Best Pract Res Clin Endocrinol Metab 26:145-57. 2012
  4. ncbi request reprint Genetic syndromes of severe insulin resistance
    Robert K Semple
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, United Kingdom
    Endocr Rev 32:498-514. 2011
  5. ncbi request reprint Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma
    David B Savage
    Department of Medicine, Addenbrooke s Hospital, Cambridge, UK
    Diabetes 52:910-7. 2003
  6. doi request reprint Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance
    Robert K Semple
    Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Diabetes Care 31:977-9. 2008
  7. ncbi request reprint Human congenital perilipin deficiency and insulin resistance
    Kristina Kozusko
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Endocr Dev 24:150-5. 2013
  8. pmc Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis
    Robert K Semple
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, United Kingdom
    J Clin Invest 119:315-22. 2009
  9. pmc Mitochondrial dysfunction in patients with primary congenital insulin resistance
    Alison Sleigh
    Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom
    J Clin Invest 121:2457-61. 2011
  10. pmc A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia
    Satya Dash
    Departments of Medicine and Clinical Biochemistry, University of Cambridge, Addenbrooke s Hospital, Cambridge, United Kingdom
    Proc Natl Acad Sci U S A 106:9350-5. 2009

Detail Information

Publications29

  1. ncbi request reprint A clinical approach to severe insulin resistance
    David B Savage
    Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK
    Endocr Dev 11:122-32. 2007
    ..In the absence of a specific diagnosis and therapy, metformin is a useful insulin sensitizer and should be used in conjunction with aggressive diet and exercise interventions...
  2. doi request reprint Lipodystrophy: metabolic insights from a rare disorder
    Isabel Huang-Doran
    Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke s Hospital, University of Cambridge, Hills Road, Cambridge CB2 0QQ, UK
    J Endocrinol 207:245-55. 2010
    ....
  3. ncbi request reprint Metabolic insights from extreme human insulin resistance phenotypes
    Anna Stears
    Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Institute of Metabolic Science, University of Cambridge, UK
    Best Pract Res Clin Endocrinol Metab 26:145-57. 2012
    ....
  4. ncbi request reprint Genetic syndromes of severe insulin resistance
    Robert K Semple
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, United Kingdom
    Endocr Rev 32:498-514. 2011
    ..We now review recent developments in understanding of genetic forms of severe insulin resistance and/or lipodystrophy and suggest a revised classification based on growing knowledge of the underlying pathophysiology...
  5. ncbi request reprint Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma
    David B Savage
    Department of Medicine, Addenbrooke s Hospital, Cambridge, UK
    Diabetes 52:910-7. 2003
    ..Although the condition is rare, the study of humans with dominant-negative mutations in PPAR-gamma can provide important insight into the roles of this nuclear receptor in human metabolism...
  6. doi request reprint Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance
    Robert K Semple
    Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Diabetes Care 31:977-9. 2008
    ..Our previous observation of paradoxical hyperadiponectinemia in insulin receptoropathy provides a possible basis for a simpler and cheaper screening test...
  7. ncbi request reprint Human congenital perilipin deficiency and insulin resistance
    Kristina Kozusko
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Endocr Dev 24:150-5. 2013
    ..They also suggest that lipolytic inhibitors may be therapeutically useful in these patients...
  8. pmc Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis
    Robert K Semple
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, United Kingdom
    J Clin Invest 119:315-22. 2009
    ....
  9. pmc Mitochondrial dysfunction in patients with primary congenital insulin resistance
    Alison Sleigh
    Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, United Kingdom
    J Clin Invest 121:2457-61. 2011
    ....
  10. pmc A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia
    Satya Dash
    Departments of Medicine and Clinical Biochemistry, University of Cambridge, Addenbrooke s Hospital, Cambridge, United Kingdom
    Proc Natl Acad Sci U S A 106:9350-5. 2009
    ..This family provides unique genetic evidence of TBC1D4 involvement in human insulin action...
  11. pmc A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice
    David B Savage
    Department of Clinical Biochemistry and Medicine, University of Cambridge, Cambridge, United Kingdom
    PLoS Med 5:e27. 2008
    ..However, the functional implications of the mutation were not known. The objective of this study was to characterise the molecular and physiological consequences of this genetic variant...
  12. doi request reprint Mouse models of inherited lipodystrophy
    David B Savage
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Dis Model Mech 2:554-62. 2009
    ....
  13. ncbi request reprint PPAR gamma as a metabolic regulator: insights from genomics and pharmacology
    David B Savage
    Department of Medicine, University of Cambridge, UK
    Expert Rev Mol Med 7:1-16. 2005
    ....
  14. doi request reprint Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance
    David B Savage
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Curr Opin Lipidol 21:329-36. 2010
    ..To summarize recent research into the mechanisms linking insulin resistance, nonalcoholic fatty liver disease and metabolic dyslipidaemia...
  15. pmc TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population
    Ruth J F Loos
    Medical Research Council Epidemiology Unit, Strangeways Research Laboratory, Cambridge, UK
    Diabetes 56:1943-7. 2007
    ....
  16. doi request reprint Complement abnormalities in acquired lipodystrophy revisited
    David B Savage
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge CB2 0QQ, United Kingdom
    J Clin Endocrinol Metab 94:10-6. 2009
    ....
  17. pmc Randomized controlled trial of the efficacy of aerobic exercise in reducing metabolic risk in healthy older people: The Hertfordshire Physical Activity Trial
    Francis M Finucane
    MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge, UK
    BMC Endocr Disord 9:15. 2009
    ..TRIAL REGISTRATION: Current Controlled Trials: ISRCTN60986572...
  18. pmc Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile
    Tuomas O Kilpeläinen
    Medical Research Council MRC Epidemiology Unit, Institute of Metabolic Science, Cambridge, UK
    Nat Genet 43:753-60. 2011
    ..Our findings provide new insights into adiposity and insulin resistance...
  19. ncbi request reprint Congenital syndromes of severe insulin resistance
    Isabel Huang-Doran
    Metabolic Research Laboratories, Institute of Metabolic Science, University of Cambridge, UK
    Pediatr Endocrinol Rev 8:190-9. 2011
    ..Here we review the general and specific features of syndromes of severe IR, summarise their classification, and recommend strategies for their subsequent investigation...
  20. ncbi request reprint Digenic inheritance of severe insulin resistance in a human pedigree
    David B Savage
    Department of Clinical Biochemistry, University of Cambridge, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
    Nat Genet 31:379-84. 2002
    ....
  21. ncbi request reprint Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization
    Terry P Combs
    Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Endocrinology 143:998-1007. 2002
    ..Furthermore, Acrp30 is likely to be a biomarker of in vivo PPARgamma activation...
  22. ncbi request reprint The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation
    Mark Gurnell
    Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge CB2 2QQ, United Kingdom
    J Clin Endocrinol Metab 88:2412-21. 2003
    ..These studies provide further support for the future development of more selective receptor modulators, targeting specific pathways to ameliorate facets of the metabolic syndrome...
  23. ncbi request reprint Mechanisms of insulin resistance in humans and possible links with inflammation
    David B Savage
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn 06510, USA
    Hypertension 45:828-33. 2005
    ..Understanding the molecular/biochemical defects responsible for insulin resistance is beginning to unveil novel therapeutic targets for treatment of the metabolic syndrome and type 2 diabetes...
  24. ncbi request reprint Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma
    Ulf Riserus
    Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, OX3 7LJ, UK
    Diabetes 54:1379-84. 2005
    ..The restored SCD activity index after rosiglitazone in PPARgamma mutation supports a pivotal role of PPARgamma function in SCD regulation...
  25. pmc Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
    David B Savage
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Clin Invest 116:817-24. 2006
    ..These studies suggest that pharmacological inhibition of Acc1 and -2 may be a novel approach in the treatment of NAFLD and hepatic insulin resistance...
  26. pmc Disordered lipid metabolism and the pathogenesis of insulin resistance
    David B Savage
    Department of Internal Medicine, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06536 8012, USA
    Physiol Rev 87:507-20. 2007
    ..in 2004, we will concentrate on human studies involving the use of isotopes and/or magnetic resonance spectroscopy, occasionally drawing on mouse models which provide additional mechanistic insight...
  27. ncbi request reprint Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance
    Cheol Soo Choi
    Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Biol Chem 282:22678-88. 2007
    ....
  28. pmc The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
    Kitt Falk Petersen
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06536, USA
    Proc Natl Acad Sci U S A 104:12587-94. 2007
    ....
  29. pmc Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity
    Cheol Soo Choi
    Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 104:16480-5. 2007
    ..Taken together with previous work demonstrating that Acc2(-/-) mice have a normal lifespan, these data suggest that Acc2 inhibition is a viable therapeutic option for the treatment of obesity and type 2 diabetes...